Early Tislelizumab May Boost Progression-Free Survival in Esophageal Cancer Edited by Amy Norton April 16, 2026

https://www.medscape.com/viewarticle/early-tislelizumab-may-boost-progression-free-survival-2026a1000bur For patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), adding the PD-1 inhibitor tislelizumab to induction chemotherapy and concurrent chemoradiotherapy (CRT) achieves a 1-year progression-free survival of 72%. However, maintenance immunotherapy provides no additional benefit and may increase toxicity.